Globus Medical Inc. Class A Common Stock vs Grab Holdings Ltd. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Grab Holdings Ltd. trades at $2.9 (market cap $12.19B). The key difference: Grab Holdings Ltd. is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Grab Holdings Ltd. for 94 Days on average.
| GMED | GRAB | |
|---|---|---|
Market Cap | $10.25B | $12.19B |
Volume | 1,108,124 | 48,418,739 |
Sector | Health | Technology |
52-Week High | $96.82 | $6.12 |
52-Week Low | $58.33 | $2.80 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $9.76B | $7.93B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
GRAB trades at $2.91, down 7.62% in the past 24 hours, with technical indicators showing bearish momentum. The company demonstrates strong fundamental improvement with revenue growing from $1.4B in 2022 to $3.37B in 2025 and achieving profitability with $268M net income. Recent developments include the $1.49B acquisition of Atome Financial and aggressive share repurchases, while management has shown confidence through significant insider buying.
GRAB presents a compelling turnaround story with accelerating revenue growth and recent profitability. The stock trades at reasonable valuations (P/E 27.09, P/S 3.65) with 92% analyst buy ratings. Key risks include integration challenges from the Atome acquisition and regional regulatory uncertainties in Southeast Asian markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →